S-P/Santarus deal
This article was originally published in The Tan Sheet
Executive Summary
Santarus announces a $5 mil. milestone relating to progress on clinical product development for proton pump inhibitor products using the company's patented PPI technology has been achieved under its over-the-counter license agreement with Schering-Plough. Santarus expects to receive the milestone within 30 days, the firm states in a July 20 release. Santarus already received a $15 million upfront license fee in November and, upon the achievement of certain regulatory and sales milestones, may receive up to an additional $60 million in milestone payments. The companies hope the proton pump inhibitor will have an edge against Procter & Gamble's Prilosec OTC in the heartburn market ( 1"The Tan Sheet" Oct. 23, 2006, p. 3)...
You may also be interested in...
Zegerid May Bring Quick Heartburn Relief To Market Under Santarus/S-P deal
Immediate-release delivery will give Santarus' proton pump inhibitor Zegerid (omeprazole/sodium bicarbonate) an edge against Prilosec OTC in the heartburn market if the firm can pull off a planned Rx-to OTC switch
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.